Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-α in malignant pleural mesothelioma

Journal of Pathology

Volumn 211, Issue 4, 2007, Pages 439-446

  Gordon, G J ^a   Mani, M ^a   Mukhopadhyay, L ^a   Dong, L ^a   Yeap, B Y ^b   Sugarbaker, D J ^a   Bueno, R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; LIVIN; MESSENGER RNA; PROTEIN; PYRROLIDINE DITHIOCARBAMATE; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PLEURA MESOTHELIOMA; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MESOTHELIOMA; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NF-KAPPA B; PLEURAL NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33847401904     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2120     Document Type: Article

References (40)

1. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nature Rev Mol Cell Biol 2002;3:401-410.
2. Deveraux Q, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula M, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-2223.
3. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-3259.
4. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003;22:8568-8580.
5. de Graaf AO, de Witte T, Jansen JH. Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer? Leukemia 2004;18:1751-1759.
6. Vischioni B, van der Valk P, Ing SWS, Kruyt FAE, Rodriguez JA, Giaccone G. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 2006;37:78-86.
7. Mayo MW, Baldwin AS. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000;1470:M55-M62.
8. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and cIAP1 and cIAP2 to suppress caspase 8 activation. Science 1998;281:1680-1683.
9. Chu Z-L, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis cIAP2 is under NF-κB control. Proc Natl Acad Sci USA 1997;94:10057-10062.
10. Sayers TJ, Murphy WJ. Combining protesome inhibition with TNF-related apoptosis inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006;55:76-84.
11. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nature Rev Cancer 2005;5:876-885.
12. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004;23:8105-8117.
13. Partanen R, Koskinen H, Hemminki K. Tumor necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer. Occup Environ Med 1995;52:316-319.
14. Hand AM, Husgafvel-Pursiainen K, Tammilehto L, Mattson K, Linnainmaa K. Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines. Cancer Lett 1991;58:205-210.
15. Corson JM, Renshaw AA. Pathology of mesothelioma. In Comprehensive Textbook of Thoracic Oncology, Aisner J, Arriagada R, Green MR, Martini N, Perry MC (eds). Williams and Wilkins: Baltimore, 1996; 757-758.
16. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005;166:1827-1840.
17. Gordon GJ, Chen C-J, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, et al. Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 2002;23:1017-1024.
18. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, et al. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007;in press. DOI:10.1002/path2121.
19. Behbehani AM, Hunter WJ, Chapman AL, Lin F. Studies of a human mesothelioma. Hum Pathol 1982;13:862-866.
20. Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood 1989;74:940-946.
21. Connell ND, Rheinwald JG. Regulation of the cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture. Cell 1983;34:245-253.
22. Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo ZS, Tsao H, et al. A two-stage, pl6(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002;22:5157-5172.
23. Gordon GJ, Hsiao L-L, Jensen RV, Gullans SR, Blumenstock JE, Richards WG, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003;95:598-605.
24. Schreck R, Baeuerle PA. A role for oxygen radicals as second messengers. Trends Cell Biol 1991;1:39-42.
25. Venables WN, Riley BD. Modern Applied Statistics with S-Plus. Springer: New York, 1997.
26. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999;13:239-252.
27. Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, Raval A, et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet 2003;12:791-801.
28. Takeuchi H, Kim JY, Fujimoto A, Umetani N, Mori T, Bilchik A, et al. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin Cancer Res 2005;11:7621-7628.
29. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simoes-Wust AP, Yousefi. S, Simon HU, et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005;117:755-763.
30. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005;7:R897-R908.
31. Gunawardena K, Campbell LD, Meikle AW. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells. Cancer Detect Prev 2005;29:389-395.
32. Hellmuth M, Wetzler C, Nold M, Chang JH, Frank S, Pfeilschifter J, et al. Expression of interleukin-8, heme oxygenase-1 and vascular endothelial growth factor in DLD-1 colon carcinoma cells exposed to pyrrolidine dithiocarbamate. Carcinogenesis 2002;23:1273-1279.
33. Moon SK, Jung SY, Choi YH, Lee YC, Patterson C, Kim CH. PDTC, metal chelating compound, induces G1 phase cell cycle arrest in vascular smooth muscle cells through inducing p21Cip1 expression: involvement of p38 mitogen activated protein kinase. J Cell Physiol 2004;198:310-323.
34. Calviello G, Filippi GM, Toesca A, Palozza P, Maggiano N, Nicuolo FD, et al. Repeated exposure to pyrrolidine-dithiocarbamate induces peripheral nerve alterations in rats. Toxicol Lett 2005;158:61-71.
35. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Rev Immunol 2003;3:745-756.
36. Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002;416:345-348.
37. Pass H. Malignant pleural mesothelioma: surgical roles and novel therapies. Clin Lung Cancer 2001;3:102-117.
38. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
39. Sugarbaker DJ, Norberto JJ, Bueno R. Current therapy for mesothelioma. Cancer Control 1997;4:326-334.
40. Russo P, Catassi A, Malacarne D, Margaritora S, Cesario A, Festi L, et al. Tumor necrosis factor enhances SN38-mediated apoptosis in mesothelioma cells. Cancer 2005;103:1503-1518.